Aarey Drugs & Pharmaceuticals Limited (524412) Fair Value & Analysis
Other · IN · Market cap ₹696M
Fair value as of: Jul 4, 2026
From 23 valuation models · updated today
Share price +9.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹50.88 – ₹99.50 · fair‑value band ₹21.94 – ₹33.23 · the ₹86.13 price screens above the ₹29.25 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aarey Drugs & Pharmaceuticals Limited (524412) currently trades at ₹86.13, while our model-based Fair Value estimate is ₹29.25 — implying the stock looks roughly 66.0% overvalued today. We read business quality at 58/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Aarey Drugs & Pharmaceuticals Limited generated revenue of ₹2.5B at a net margin of 2.4%. Revenue declined 17.6% year over year. The stock trades on a trailing P/E of 10.5. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, bulk drugs, intermediates, and specialty chemicals for various industrial applications in India. The company offers mono methyl and dimethyl urea, theobromine, mefanamic acid, bromomethyl, and dioxolane. It also offers chemicals and solvents, which include aeromatics chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals. The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. It also trades in industrial solvents and chemicals. The company was formerly known as Niharika Textiles & Chemicals Private Limited and changed its name to Aarey Drugs & Pharmaceuticals Limited in March 1993. Aarey Drugs & …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aarey Drugs & Pharmaceuticals Limited reported revenue of ₹4.7B in FY2025 versus ₹3.5B in FY2021, a compound +8.0%/yr. Reported net income was ₹40.2M in FY2025, compounding −11.3%/yr from FY2021.
Is 524412 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Aarey Drugs & Pharmaceuticals Limited (524412) undervalued?
What is the fair value of 524412?
What is the quality score of 524412?
What is the revenue of Aarey Drugs & Pharmaceuticals Limited (524412)?
What is the net profit margin of 524412?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.